Filed with the SEC on · accession 0001193125-26-452672
HRTX filed a 8-K (current report) with the SEC on Nov 9, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Heron Therapeutics agreed to sell substantially all of its assets to CorMedix Inc. for $145 million in cash plus 14,583,333 shares of CorMedix common stock, along with royalty and earn-out payments, while retaining its NOLs and certain other assets.
✦ Ask GOAX AI about this filing — what it means for HRTX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for HRTX?
Click hereHRTX filed a 8-K (Divestiture). Heron Therapeutics agreed to sell substantially all of its assets to CorMedix Inc. for $145 million in cash plus 14,583,333 shares of CorMedix common stock, along with royalty and earn-out payments, while retaining its NOLs and certain other assets.
A contract important enough that investors need to know about it — a big customer contract, a loan, a merger agreement or a partnership.
A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.
Get alerts when HRTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days